We narrowed to 1,077 results for: aav

#228902-AAV8

Ready-to-use AAV8 particles produced from pAAV-CAG-DIO-HA-HCARD-P2A-mCitrine (#228902). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-HA-HCARD-P2A-mCitrine plasmid DNA. CAG-driven, Cre dependent expression of a peripherally restricted DREADD. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Kang et al Cell. 2024 Dec 26;187(26):7433-7449.e20.

Oct. 8, 2025

Academic Institutions and Nonprofits only

#213833-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiCHATe27_GCaMP6f (#213833). In addition to the viral particles, you will also receive purified pAAV_BiCHATe27_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the cholinergic neuron-targeting enhancer E27. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213918-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiLAMP5e3_jGCaMP8m (#213918). In addition to the viral particles, you will also receive purified pAAV_BiLAMP5e3_jGCaMP8m plasmid DNA. Expression of jGCaMP8m under the control of the Lamp5 interneuron-targeting enhancer E3. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213917-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiLAMP5e3_GCaMP6f (#213917). In addition to the viral particles, you will also receive purified pAAV_BiLAMP5e3_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the Lamp5 interneuron-targeting enhancer E3. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#221463-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiPVe4_eGFP (#221463). In addition to the viral particles, you will also receive purified pAAV_BiPVe4_eGFP plasmid DNA. Expression of EGFP under the control of the chandelier cell-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#37825-AAV11

Ready-to-use AAV11 particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. CAG-driven GFP expression. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

July 16, 2025

Academic Institutions and Nonprofits only

#135641-AAV1

Ready-to-use AAV1 particles produced from pAAV-S5E6-dTom-nlsdTom (#135641). In addition to the viral particles, you will also receive purified pAAV-S5E6-dTom-nlsdTom plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato in VIP cortical interneurons under the control of the E6 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Feb. 6, 2025

Academic Institutions and Nonprofits only

#99118-AAV2

Ready-to-use AAV2 particles produced from pAAV-CAG-tTA (#99118). In addition to the viral particles, you will also receive purified pAAV-CAG-tTA plasmid DNA. CAG-driven expression of tetracycline-controlled transactivator (tTA). These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Chan et al Nat Neurosci. 2017 Aug;20(8):1172-1179.

June 26, 2024

Academic Institutions and Nonprofits only

#83894-AAV2

Ready-to-use AAV2 particles produced from pAAV-hDlx-Flex-dTomato-Fishell_7 (#83894). In addition to the viral particles, you will also receive purified pAAV-hDlx-Flex-dTomato-Fishell_7 plasmid DNA. hDlx-driven, Cre-dependent expression of dTomato. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Feb. 5, 2024

Academic Institutions and Nonprofits only

#138328-AAV9

Ready-to-use AAV9 particles produced from pAAV-synapsin-HaloCaMP1b-EGFP (#138328). In addition to the viral particles, you will also receive purified pAAV-synapsin-HaloCaMP1b-EGFP plasmid DNA. Synapsin-driven HaloCaMP1b, a far-red calcium sensor, fused to EGFP. These AAV preparations are suitable purity for injection into animals.

Eric Schreiter

Deo et al Nat Chem Biol. 2021 Jun;17(6):718-723. d

Sept. 15, 2021

Academic Institutions and Nonprofits only

#138327-AAV9

Ready-to-use AAV9 particles produced from pAAV-synapsin-HaloCaMP1a-EGFP (#138327). In addition to the viral particles, you will also receive purified pAAV-synapsin-HaloCaMP1a-EGFP plasmid DNA. Synapsin-driven HaloCaMP1a, a far-red calcium sensor, fused to EGFP. These AAV preparations are suitable purity for injection into animals.

Eric Schreiter

Deo et al Nat Chem Biol. 2021 Jun;17(6):718-723. d

Sept. 15, 2021

Academic Institutions and Nonprofits only

#209658-AAV5

Ready-to-use AAV5 particles produced from pAAV.CAGFLEX.(cyto).cpSFGFP.HaloTag (#209658). In addition to the viral particles, you will also receive purified pAAV.CAGFLEX.(cyto).cpSFGFP.HaloTag plasmid DNA. CAG-driven, Cre-dependent expression of cpSFGFP.HaloTag (non-responsive control). These AAV preparations are suitable purity for injection into animals.

Tim Brown, HHMI-JRC Tool Translation Team

Marvin et al Proc Natl Acad Sci U S A. 2024 May 21;12

Oct. 29, 2025

Academic Institutions and Nonprofits only

#98928-AAV5

Ready-to-use AAV5 particles produced from pAAV.CAG.Flex.Ruby2sm-Flag.WPRE.SV40 (#98928). In addition to the viral particles, you will also receive purified pAAV.CAG.Flex.Ruby2sm-Flag.WPRE.SV40 plasmid DNA. CAG-driven, Cre-dependent expression of Ruby2sm-Flag spaghetti monster construct. Spaghetti monster constructs are not fluorescent ("dark") to allow full range of antibody staining. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Viswanathan et al Nat Methods. 2015 Jun;12(6):568-76. doi:

Oct. 29, 2025

Academic Institutions and Nonprofits only

#236288-AAV8

Ready-to-use AAV8 particles produced from pAAV.TBG.PI.FLPo.rBG (#236288). In addition to the viral particles, you will also receive purified pAAV.TBG.PI.FLPo.rBG plasmid DNA. TBG-driven expression of the recombinase FLPo. These AAV preparations are suitable purity for injection into animals.

Melina Fan, Addgene Research Program

Oct. 23, 2025

Academic Institutions and Nonprofits only

#213915-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiLAMP5e3_ChR2_mCherry (#213915). In addition to the viral particles, you will also receive purified pAAV_BiLAMP5e3_ChR2_mCherry plasmid DNA. Expression of mCherry-tagged channelrhodopsin-2 under the control of the Lamp5 interneuron-targeting enhancer E3. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#112004-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSynapsin1-axon-GCaMP6s-P2A-mKate2 (#112004). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-axon-GCaMP6s-P2A-mKate2 plasmid DNA. Synapsin-driven, axon-targeted GCaMP6s calcium sensor and bicistronic mKate2 expression. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Broussard et al Nat Neurosci. 2018 Sep;21(9):1272-1280.

Feb. 14, 2022

Academic Institutions and Nonprofits only

#140136-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-iDreV (#140136). In addition to the viral particles, you will also receive purified pAAV-EF1a-iDreV plasmid DNA. EF1a-driven, light-inducible iDreV recombinase for spatiotemporally precise optogenomic modifications. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Yao et al Nat Methods. 2020 Mar 23. pii: 10.1038/s

Oct. 28, 2021

Academic Institutions and Nonprofits only